Pacific Biosciences Q2 adj. loss bigger than estimates on margin pressure
PACB•Q2 results miss estimates
Pacific Biosciences reported second-quarter revenue of $39 million, missing the consensus estimate of $40.07 million from seven analysts. Revenue declined year over year.
The company also reported an adjusted loss per share of $0.14, wider than the consensus estimate of $0.13 from five analysts. Adjusted net loss was $41.90 million, compared with the consensus estimate of $39.25 million.
Adjusted gross margin was 36.00%, and adjusted gross profit was $13.90 million.
Margin pressure and outlook
PacBio said lower gross margin was primarily due to higher compute and memory costs, Vega manufacturing transition costs, and lower Revio average selling prices for strategic multi-system placements.
Revenue was driven by growing consumables and new Revio and Vega placements as the company commenced the full rollout of SPRQ-Nx chemistry.
The company said it expects 2026 revenue between $155 million and $165 million. It also said it implemented restructuring actions to streamline marketing and R&D and strengthen its commercial organization.
